For example, there is a phase II, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in 5 cohorts, including 30 pretreated patients with HER2-positive or HER2-negative BC with HER2-activating mutations (NCT04172597). Here, ERBB2 is linked to breast cancer.